Skip to main content

Table 1 Characteristics of the included RCTs of SAMe in MDD

From: S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review

Author Study typology Duration Dose SAMe Administration Primary outcome Diagnostic criteria
Caruso 1984 [36] SAMe vs PBO 3 weeks 200 mg/day IM HAM-D (21 items) Not specified
Kagan 1990 [37] SAMe vs PBO 3 weeks 200 mg/day OR HAM-D (21 items) DSM-III
Berlanga 1992 [38] SAMe + IMI vs PBO + IMI 2 weeks 200 mg/day IM HAM-D (17 items) DSM-III-R
Papakostas 2010 [39] SAMe + SRI vs PBO + SRI 6 weeks 800 mg/day OR HAM-D DSM-IV
Delle Chiaie 2002a [40] SAMe vs IMI 6 weeks 1600 mg/day OR HAM-D (21 items) DSM-IV
Delle Chiaie 2002b [40] SAMe vs IMI 4 weeks 400 mg/day IM HAM-D (21 items) DSM-IV
Mischoulon 2014a [41] SAMe vs PBO 12 weeks 1600–3200 mg/day OR HAM-D (17 items) IDS-C ≥ 25
Mischoulon 2014b [41] SAMe vs EST 12 weeks 1600–3200 mg/day OR HAM-D (17 items) IDS-C ≥ 25
Sarris 2014a [42] SAMe vs PBO 12 weeks 1600 mg/day OR HAM-D (17 items) DSM-IV
Sarris 2014b [42] SAMe vs EST 12 weeks 1600 mg/day OR HAM-D (17 items) DSM-IV
Sarris 2018 [43] SAMe vs PBO 8 weeks 800 mg/day OR MADRS DSM-V
  1. IM intramuscular, OR oral, PBO placebo, IMI imipramine, EST escitalopram, MDD major depressive disorder, SAMe S-Adenosylmethionine, SRI serotonin reuptake inhibitors